Comparison of the Permeability of Metoprolol and Labetalol in Rat, Mouse, and Caco-2 Cells: Use As a Reference Standard for BCS Classification

Overview

Journal Mol Pharm

Publisher American Chemical Society

Specialty Pharmacology

Date 2013 Jan 19

PMID 23327720

Citations 21

Authors

Tuba Incecayir

Yasuhiro Tsume

Gordon L Amidon

Affiliations

Soon will be listed here.

Abstract

The purpose of this study was to investigate labetalol as a potential high permeability reference standard for the application of Biopharmaceutics Classification Systems (BCS). Permeabilities of labetalol and metoprolol were investigated in animal intestinal perfusion models and Caco-2 cell monolayers. After isolating specific intestinal segments, in situ single-pass intestinal perfusions (SPIP) were performed in rats and mice. The effective permeabilities (Peff) of labetalol and metoprolol, an FDA standard for the low/high Peff class boundary, were investigated in two different segments of rat intestine (proximal jejunum and distal ileum) and in the proximal jejunum of mouse. No significant difference was found between Peff of metoprolol and labetalol in the jejunum and ileum of rat (0.33 ± 0.11 × 10(-4) vs 0.38 ± 0.06 × 10(-4) and 0.57 ± 0.17 × 10(-4) vs 0.64 ± 0.30 × 10(-4) cm/s, respectively) and in the jejunum of mouse (0.55 ± 0.05 × 10(-4) vs 0.59 ± 0.13 × 10(-4) cm/s). However, Peff of metoprolol and labetalol were 1.7 and 1.6 times higher in the jejunum of mouse, compared to the jejunum of rat, respectively. Metoprolol and labetalol showed segmental-dependent permeability through the rat intestine, with increased Peff in the distal ileum in comparison to the proximal jejunum. Most significantly, Peff of labetalol was found to be concentration-dependent. Decreasing concentrations of labetalol in the perfusate resulted in decreased Peff compared to Peff of metoprolol. The intestinal epithelial permeability of labetalol was lower than that of metoprolol in Caco-2 cells at both apical pH 6.5 and 7.5 (5.96 ± 1.96 × 10(-6) vs 9.44 ± 3.44 × 10(-6) and 15.9 ± 2.2 × 10(-6) vs 23.2 ± 7.1 × 10(-6) cm/s, respectively). Labetalol exhibited higher permeability in basolateral to apical (BL-AP) compared to AP-BL direction in Caco-2 cells at 0.1 times the highest dose strength (HDS) (46.7 ± 6.5 × 10(-6) vs 14.2 ± 1.5 × 10(-6) cm/s). The P-gp inhibitor, verapamil, significantly increased AP-BL and decreased BL-AP direction transport of labetalol. Overall, labetalol showed high Peff in rat and mouse intestinal perfusion models similar to metoprolol at a concentration based on HDS. However, the concentration-dependent permeability of labetalol in mice due to P-gp and the inhibition study with verapamil in Caco-2 cells indicated that labetalol is not an ideal reference standard for BCS classification.

Citing Articles

Challenges in Permeability Assessment for Oral Drug Product Development.

Koziolek M, Augustijns P, Berger C, Cristofoletti R, Dahlgren D, Keemink J Pharmaceutics. 2023; 15(10).

PMID: 37896157 PMC: 10609725. DOI: 10.3390/pharmaceutics15102397.

Canine Intestinal Organoids as a Novel In Vitro Model of Intestinal Drug Permeability: A Proof-of-Concept Study.

Sahoo D, Martinez M, Dao K, Gabriel V, Zdyrski C, Jergens A Cells. 2023; 12(9).

PMID: 37174669 PMC: 10177590. DOI: 10.3390/cells12091269.

Exploring a Bioequivalence Failure for Silodosin Products Due to Disintegrant Excipients.

Gonzalez-Alvarez I, Sanchez-Dengra B, Rodriguez-Galvez R, Ruiz-Picazo A, Gonzalez-Alvarez M, Garcia-Arieta A Pharmaceutics. 2022; 14(12).

PMID: 36559059 PMC: 9783061. DOI: 10.3390/pharmaceutics14122565.

Preclinical Characterization and Development on NAQ as a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment.

Pagare P, Obeng S, Huang B, Marcus M, Nicholson K, Townsend A ACS Pharmacol Transl Sci. 2022; 5(11):1197-1209.

PMID: 36407950 PMC: 9667545. DOI: 10.1021/acsptsci.2c00178.

Fighting Plasmodium chloroquine resistance with acetylenic chloroquine analogues.

Cortopassi W, Gunderson E, Annunciato Y, Silva A, Dos Santos Ferreira A, Teles C Int J Parasitol Drugs Drug Resist. 2022; 20:121-128.

PMID: 36375339 PMC: 9771834. DOI: 10.1016/j.ijpddr.2022.10.003.

References

Vidon N, Evard D, Godbillon J, Rongier M, Duval M, SCHOELLER J . Investigation of drug absorption from the gastrointestinal tract of man. II. Metoprolol in the jejunum and ileum. Br J Clin Pharmacol. 1985; 19 Suppl 2:107S-112S. PMC: 1463762. DOI: 10.1111/j.1365-2125.1985.tb02750.x. View

Dahan A, Miller J, Hilfinger J, Yamashita S, Yu L, Lennernas H . High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. Mol Pharm. 2010; 7(5):1827-34. DOI: 10.1021/mp100175a. View

Neuhoff S, Ungell A, Zamora I, Artursson P . pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res. 2003; 20(8):1141-8. DOI: 10.1023/a:1025032511040. View

Lee K, Johnson N, Castelo J, Sinko P, Grass G, Holme K . Effect of experimental pH on the in vitro permeability in intact rabbit intestines and Caco-2 monolayer. Eur J Pharm Sci. 2005; 25(2-3):193-200. DOI: 10.1016/j.ejps.2005.02.012. View

Fujimura A, Ohashi K, Tsuru M, Ebihara A, Kondo K . Clinical pharmacology of dilevalol (I). Comparison of the pharmacokinetic and pharmacodynamic properties of dilevalol and labetalol after a single oral administration in healthy subjects. J Clin Pharmacol. 1989; 29(7):635-42. DOI: 10.1002/j.1552-4604.1989.tb03392.x. View

Chen M, Amidon G, Benet L, Lennernas H, Yu L . The BCS, BDDCS, and regulatory guidances. Pharm Res. 2011; 28(7):1774-8. DOI: 10.1007/s11095-011-0438-1. View

Cao X, Yu L, Barbaciru C, Landowski C, Shin H, Gibbs S . Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. Mol Pharm. 2005; 2(4):329-40. DOI: 10.1021/mp0499104. View

Valenzuela B, Nacher A, Ruiz-Carretero P, Martin-Villodre A, Lopez-Carballo G, Barettino D . Profile of P-glycoprotein distribution in the rat and its possible influence on the salbutamol intestinal absorption process. J Pharm Sci. 2004; 93(6):1641-8. DOI: 10.1002/jps.20071. View

Thiel-Demby V, Humphreys J, St John Williams L, Ellens H, Shah N, Ayrton A . Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay. Mol Pharm. 2009; 6(1):11-8. DOI: 10.1021/mp800122b. View

10.

Moss A, Endres C, Ruiz-Garcia A, Choi D, Unadkat J . Role of the equilibrative and concentrative nucleoside transporters in the intestinal absorption of the nucleoside drug, ribavirin, in wild-type and Ent1(-/-) mice. Mol Pharm. 2012; 9(9):2442-9. PMC: 3443246. DOI: 10.1021/mp200647a. View

11.

Wagner J, Ganes D, Midha K, Sackellares J, Olson L, Affrime M . Stepwise determination of multicompartment disposition and absorption parameters from extravascular concentration-time data. Application to mesoridazine, flurbiprofen, flunarizine, labetalol, and diazepam. J Pharmacokinet Biopharm. 1991; 19(4):413-55. DOI: 10.1007/BF01061665. View

12.

Fagerholm U, Johansson M, Lennernas H . Comparison between permeability coefficients in rat and human jejunum. Pharm Res. 1996; 13(9):1336-42. DOI: 10.1023/a:1016065715308. View

13.

Meier J . Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents. Am Heart J. 1982; 104(2 Pt 2):364-73. DOI: 10.1016/0002-8703(82)90127-2. View

14.

Hubatsch I, Ragnarsson E, Artursson P . Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc. 2007; 2(9):2111-9. DOI: 10.1038/nprot.2007.303. View

15.

Dahan A, Amidon G . Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm. 2009; 6(1):19-28. DOI: 10.1021/mp800088f. View

16.

Dahan A, Amidon G . Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein. Pharm Res. 2008; 26(4):883-92. DOI: 10.1007/s11095-008-9789-7. View

17.

Shalaeva M, Kenseth J, Lombardo F, Bastin A . Measurement of dissociation constants (pKa values) of organic compounds by multiplexed capillary electrophoresis using aqueous and cosolvent buffers. J Pharm Sci. 2008; 97(7):2581-606. DOI: 10.1002/jps.21287. View

18.

Lennernas H, Abrahamsson B . The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol. 2005; 57(3):273-85. DOI: 10.1211/0022357055263. View

19.

Escribano E, Sala X, Salamanca J, Navarro C, Queralt Regue J . Single-pass intestinal perfusion to establish the intestinal permeability of model drugs in mouse. Int J Pharm. 2012; 436(1-2):472-7. DOI: 10.1016/j.ijpharm.2012.07.010. View

20.

Kim J, Mitchell S, Kijek P, Tsume Y, Hilfinger J, Amidon G . The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. Mol Pharm. 2006; 3(6):686-94. DOI: 10.1021/mp060042f. View